This is a quickly progressing field, according to Sarju Patel, MD, attending physician at Retinal Consultants of America. He has high expectations that advances from subtly tinted eyeglass lenses to ...

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 ...

Please provide your email address to receive an email when new articles are posted on . EYP-1901 and OTX-TKI have shown results similar to aflibercept 2 mg. Gene therapy is another type of treatment ...

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

For sura-vec in wet AMD, top line data from pivotal studies ATMOSPHERE and ASCENT are anticipated in Q4. First patient dosing in NAVIGATE for diabetic retinopathy is planned next quarter, expected to ...

EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (FDMT) (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and ...

The MarketWatch News Department was not involved in the creation of this content. Darius M. Moshfeghi, Chief of the Retina Division at Byers Eye Institute of Stanford University School of Medicine ...

VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and ...

Julie Rosenthal, MD, MS, discusses signs and symptoms of age-related macular degeneration as well as methods of treatment. Rosenthal: Some people don't have any symptoms at all when the disease is ...

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable ...